Annexon (NASDAQ:ANNX) Sees Unusually-High Trading Volume

Annexon, Inc. (NASDAQ:ANNXGet Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,486,074 shares were traded during trading, a decline of 26% from the previous session’s volume of 1,999,839 shares.The stock last traded at $5.91 and had previously closed at $5.99.

Analyst Ratings Changes

A number of research firms have weighed in on ANNX. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Annexon in a research report on Tuesday. Wells Fargo & Company lowered their price objective on shares of Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 15th. JPMorgan Chase & Co. upped their price objective on shares of Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, April 1st. Bank of America lifted their target price on shares of Annexon from $7.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Tuesday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.33.

Check Out Our Latest Report on ANNX

Annexon Trading Down 13.3 %

The stock’s 50 day moving average price is $5.18 and its two-hundred day moving average price is $4.72. The firm has a market capitalization of $544.29 million, a price-to-earnings ratio of -4.01 and a beta of 1.30.

Annexon (NASDAQ:ANNXGet Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11. On average, sell-side analysts forecast that Annexon, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently bought and sold shares of ANNX. Ameritas Investment Partners Inc. increased its position in shares of Annexon by 78.2% in the first quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock valued at $48,000 after buying an additional 2,949 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Annexon by 53.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock valued at $54,000 after purchasing an additional 4,141 shares during the last quarter. Comerica Bank acquired a new stake in shares of Annexon in the first quarter valued at approximately $72,000. ProShare Advisors LLC purchased a new position in shares of Annexon during the 1st quarter worth approximately $87,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Annexon during the 1st quarter worth approximately $98,000.

About Annexon

(Get Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Featured Stories

Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.